Aminalon (aminolone) coated tablets 0.25 №50

active ingredient: gamma-aminobutyric acid (GABA);

1 tablet contains gamma-aminobutyric acid (GABA) (in terms of 100% substance) 250 mg;

excipients : microcrystalline cellulose, povidone 25, anhydrous colloidal silicon dioxide, magnesium stearate, opadry II white 85F18422 (mixture of substances: polyethylene glycol, talc, titanium dioxide (E 171), polyvinyl alcohol).

Coated tablets.

Basic physical and chemical properties: tablets of a round shape with a biconvex surface, coated white or white with a creamy tint.

Psychoanaleptics. Other psychostimulants and nootropics. ATX code N06B X.

Gamma-aminobutyric acid (GABA) is the main mediator of the central nervous system involved in the processes of central inhibition. Under its influence, the energy processes of the brain are activated, the utilization of glucose by the latter improves, the respiratory activity of tissues increases, and blood supply improves. The drug improves the dynamics of nervous processes in the brain, thinking, memory, attention, helps to restore movements and speech after a violation of cerebral circulation, and has a mild psychostimulating effect.

It helps to reduce and stabilize high blood pressure (BP) and reduce the subjective symptoms of arterial hypertension (dizziness, sleep disturbance). It has a moderate antihypotoxic and anticonvulsant effect. In patients with diabetes mellitus, it reduces the content of glucose, with a normal content of glucose in the blood, it has the opposite effect (due to glycogenolysis). By the nature of the action, the drug is similar to nootropics.

As part of the complex treatment of diseases of the central nervous system:

• vascular diseases of the brain (atherosclerosis, lesions of cerebral vessels in arterial hypertension);
• chronic cerebrovascular insufficiency with impaired memory, concentration, speech, dizziness, headaches;
• encephalopathy (alcoholic, post-stroke, post-traumatic);
• cerebral palsy;
• mental retardation in children (over 5 years old);
• senile dementia (initial stages of dementia);
• sea ​​and air sickness (for the prevention and treatment of motion sickness symptom complex).

Hypersensitivity to any components of the drug. Acute renal failure.